• Join
  • Login
  • Contact

Search abstracts

Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis

  • In: Poster presentation
  • At: Buenos Aires (Argentina) (2016)
  • Type: Poster
  • Poster code: POS-CPS-097
  • By: YOO, Bong-Kyu (College of Pharmacy, Gachon University, Inchon, Korea, Republic Of)
  • Co-author(s): Bong-Kyu Yoo:|Eunhee Ji:College of Pharmacy,Gachon University,Incheon,Korea, Republic Of|Ju Yeon Ryoo:College of Pharmacy,Gachon University,Incheon,Korea, Republic Of|Hye-Jin Yang:College of Pharmacy,Gachon University,Incheon,Korea, Republic Of
  • Abstract:

    In January 2015, US FDA approved secukinumab, a human interleukin-17A (IL-17A) antagonist, for the treatment of plaque psoriasis.

    PubMed and EMBASE database searches were conducted. Among the literatures retrieved, relevant Phase III clinical trials were analyzed. Statistical analysis of the data was performed by RevMan.

    Four pivotal and three


  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses